Table 3

Candidate areas with chromosomal alterations characterizing non-muscle invasive bladder cancers with subsequent progression.

Chromosome

Cytoband

Physical position (hg17/NCBI build 35.1)

chromosomal changes of progressing tumors

Candidate genes (selection)

p (single SNPs)

p (segment)

1

p31.1-p22.3

82–86 Mb

CN gain

BCL10

0.003

n.s.

2

q33.3-q34

208–213 Mb

CN gain

CREB1, MAP2

0.001

0.05

3

p21-p14.3

42–64 Mb

CN gain

CCR-cluster

0.01

n.s.

4

p13

40–45 Mb

CN loss/LOH

0.02

n.s.

6

q15-q23.2

89–133 Mb

CN loss/LOH

TPD52L1

0.01

n.s.

8

p12-p11.21

33 M–43 Mb

CN loss/LOH

SFRP1, TACC1, FGFR1

0.01

n.s.

10

p15.1-p14

3.5 M–13 Mb

CN gain

GATA3, NET1, PKCQ, IL15RA

0.005

n.s.

10

p11

30–36 Mb

CN gain

0.005

n.s.

15

q25.3

84–85 Mb

CN loss

0.01

n.s.

SNP microarray analysis (significance p = probability of detecting difference between progressing and non-progressing tumors by chance, permutation analysis). A survey of the entire genome is possible in Additional Files 2, 3, 4 and 5.

Zieger et al. BMC Cancer 2009 9:149   doi:10.1186/1471-2407-9-149